RE:RE:RE:RE:I am a bit bipolar Statically overall success rate for preclinical cancer trials is about a bit over 3% from P1 to P2 over 50%, from P2 to P3 over 30% same for P3 to approval. So although very general their purchase of Katana had only over 3% chance of success. As Wino mentioned big pharmas with great balance sheets won't take those chances as they are already either commercializing their drugs and have sizeable revenues and/or are involved with more advanced programs in regards to the progress of the programs. Now we are passed that 3% threshold and again statically a phase 1 clinical trial has statically about 16% chance to overall approval, better odds, new innovative science(PDC) and targeting multiple cancers will put THTX in a great position to attract partners in various jurisdictions as their patent geographically covers more than 80% of the world. Still early but that's the potential.
https://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845